Sugi Predict

Sugi Predict / Targets / RXRB

RXRB

Retinoic acid receptor RXR-beta · P28702 · RXRB on Sugi Atlas →

110,083 patent compounds predicted against RXRB, 56,789 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Oxaprozin Oxaprozin (SCHEMBL3286) 1.00 19/20
Oxaprozin Oxaprozin (SCHEMBL137988) 0.97 19/20
Oxaprozin Oxaprozin (SCHEMBL168745) 0.49 11/20
SCHEMBL110818 SCHEMBL110818 0.42 11/20
SCHEMBL177719 SCHEMBL177719 0.73 10/20
SCHEMBL177720 SCHEMBL177720 0.73 10/20
Tamibarotene Tamibarotene (SCHEMBL36207) 0.62 9/20
SCHEMBL153296 SCHEMBL153296 0.67 8/20
SCHEMBL76093 SCHEMBL76093 0.50 8/20
(+)-Abscisic Acid (+)-Abscisic Acid (SCHEMBL33612) 0.42 8/20
(+)-Abscisic Acid (+)-Abscisic Acid (SCHEMBL33613) 0.42 8/20
Abscisic Acid Abscisic Acid (SCHEMBL33614) 0.42 8/20
SCHEMBL159738 SCHEMBL159738 0.37 8/20
Bexarotene Bexarotene (SCHEMBL9025) 1.00 7/20
SCHEMBL78581 SCHEMBL78581 0.50 7/20
SCHEMBL88554 SCHEMBL88554 0.50 7/20
SCHEMBL177444 SCHEMBL177444 0.72 6/20
SCHEMBL142861 SCHEMBL142861 0.71 6/20
SCHEMBL69066 SCHEMBL69066 0.63 6/20
SCHEMBL156460 SCHEMBL156460 0.63 6/20

Clinical trials — most relevant to RXRB by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Investigating the Potential Role of Aerosolized Retinoic Acid, a Potent Vitamin A Metabolite for Treating COVID-19 Anosmia and Retinoic Acid Insufficiency .A Novel Approach for Regaining Sense of Smell. PHASE4UNKNOWN
Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 ( Isotretinoin in Treatment of COVID-19) (Randomized) PHASE3UNKNOWN
Efficacy and Safety of Two Doses of Liarozole vs. Placebo for the Treatment of Lamellar Ichthyosis PHASE2/PHASE3COMPLETED
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia PHASE3COMPLETED
Effect of All-trans Retinoic Acid With Chemotherapy Based on Paclitaxel and Cisplatin As First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer and Expression of RAR-alfa and RAR-beta as Response Biomarker PHASE3UNKNOWN
Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma PHASE3COMPLETED
Aerosol Combination Therapy of All-trans Retinoic Acid and Isotretinoin as A Novel Treatment for Inducing Neutralizing Antibodies in COVID -19 Infected Patients Better Than Vaccine : An Innovative Treatment PHASE2UNKNOWN
Oral NRX 194204 Study in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) PHASE2UNKNOWN
Efatutazone Dihydrochloride in Treating Patients With Previously Treated Myxoid Liposarcoma That Cannot Be Removed by Surgery PHASE2COMPLETED
Study of Oral Bexarotene in Combination With Photopheresis for Treatment of Cutaneous T-Cell Lymphoma PHASE1/PHASE2COMPLETED
Efficacy and Safety of Tamibarotene(AM80) for Lupus Nephritis PHASE2UNKNOWN
Investigating the Role of 13cis Retinoic Acid in the Treatment of COVID-19 and Enhancement of Its Spike Protein Based Vaccine Efficacy and Safety. PHASE1/PHASE2UNKNOWN
Efficacy of Docosahexaenoic Acid on Tardive Dyskinesia PHASE2WITHDRAWN
A Study of Bezafibrate in Mitochondrial Myopathy PHASE2COMPLETED
Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma PHASE1/PHASE2COMPLETED
Efficacy and Safety of Drug Combination Therapy of Isotretinoin and Some Antifungal Drugs as A Potential Aerosol Therapy for COVID-19 : An Innovative Therapeutic Approach COVID-19 PHASE2UNKNOWN
TESRA: (Treatment of Emphysema With a Gamma-Selective Retinoid Agonist) PHASE2COMPLETED
5-azacytidine Valproic Acid and ATRA in AML and High Risk MDS PHASE2COMPLETED
Feasibility of Retinoic Acid Treatment in Emphysema (FORTE) PHASE2COMPLETED
Belinostat and Isotretinoin in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery PHASE1COMPLETED
Treatment of Acute Myeloid Leukemia With Arsenic and All-trans Retinoid Acid PHASE1UNKNOWN
A Clinical Trial Evaluating the Safety and Efficacy of Intravenous CD-801 in Treating Advanced HCC Patients EARLY_PHASE1RECRUITING
A Clinical Trial for the Safety and Efficacy of CD-801 in Patients With Advanced Hepatocellular Carcinoma EARLY_PHASE1COMPLETED
RORC Genetic Polymorphism of Rheumatoid Arthritis nanCOMPLETED
Prevalence Of Vitamin A Deficiency In Critically Ill Children With Sepsis And Its Association With Clinical Outcomes nanCOMPLETED
Replacement of Vitamin D in Patients With Active Tuberculosis nanCOMPLETED
Retinoic Acid Homeostasis in Neuropsychiatric Diseases nanUNKNOWN
Assessing the Effects of Alfacalcidol Intake on Expression of Involed Gene in Metabolism in Obese Subjects nanUNKNOWN
The Role of Programmed Death Ligand -1 (Pdl-1) in Lung Cancer nanCOMPLETED
PPAR, RXR, and VDR Expressions in Diabetes nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a RXRB binder may also engage these)

ProteinNameSimilarity
Q5TJF7 — 1.000 Q5TJF7 →
P28704 — 1.000 P28704 →
NR4A3 Nuclear receptor subfamily 4 group A member 3 0.998 landscape →
NR4A1 Nuclear receptor subfamily 4immunitygroup A member 1 0.998 landscape →
Q64249 — 0.997 Q64249 →
P33242 — 0.997 P33242 →
P51128 — 0.997 P51128 →
P49743 — 0.997 P49743 →
P12813 — 0.997 P12813 →
P28700 — 0.996 P28700 →
P51179 — 0.996 P51179 →
Q9QZB6 — 0.996 Q9QZB6 →
Q7SYN5 — 0.996 Q7SYN5 →
Q9GKL2 — 0.996 Q9GKL2 →
NR5A1 Steroidogenic factor 1 0.996 landscape →
NR1H2 Oxysterols receptor LXR-beta 0.995 landscape →
Q95L87 — 0.995 Q95L87 →
Q3UV55 — 0.995 Q3UV55 →
P16058 — 0.995 P16058 →
Q08E02 — 0.994 Q08E02 →
P22829 — 0.994 P22829 →
Q63503 — 0.994 Q63503 →
O14512 — 0.993 O14512 →
Q6QMY5 — 0.993 Q6QMY5 →
RXRA Retinoic acid receptor RXR-alpha 0.993 landscape →
P50241 — 0.993 P50241 →
Q5QJV7 — 0.993 Q5QJV7 →
O76202 — 0.993 O76202 →
Q9YH33 — 0.993 Q9YH33 →
P19091 — 0.993 P19091 →